Diabetes affects millions of people worldwide, and finding a cure for it has been a challenge for decades. But a new startup, DiogenX, is making strides in the field of biotechnology by focusing on regenerating insulin-producing beta cells. Founded by Benjamin CHARLES, Their lead drug candidate is a novel recombinant protein that modulates the Wnt/β-catenin signaling pathway in pancreatic beta cells, a pathway known to induce their replication. With this breakthrough discovery from the laboratory of Dr. Patrick Collombat, DiogenX aims to offer a disease-modifying therapy for type 1 diabetes by restoring functional pancreatic function. 

The company has already achieved a first proof of principle with a significant increase in functional insulin-producing human beta cells in preclinical experiments, and long-term exposure was well-tolerated in animal studies. With a recent Series A funding round of $30M from investors, DiogenX is poised to make a significant impact in the biotech industry. Based in Marseille, France, the company is committed to discovering and developing innovative biologics to offer new therapeutic options for millions of diabetic patients worldwide.